Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. - Wikidata - awgldk - TriplyDB

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

http://www.wikidata.org/entity/Q33407093

about

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Targeting angiogenesis in advanced cervical cancer.Angiogenesis and antiangiogenic agents in cervical cancer.New molecular targets against cervical cancer.Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.Adjuvant chemotherapy for early-stage cervical cancer.Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Emerging biological treatments for uterine cervical carcinoma.Emerging drugs for the treatment of cervical cancer.Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.Emerging therapies: angiogenesis inhibitors for ovarian cancer.Changing paradigms in the systemic treatment of advanced cervical cancer.Immunotherapy and targeted therapy for cervical cancer: an update.The safety of drug treatments for cervical cancer.Bevacizumab for the treatment of cervical cancer.The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.Investigational drugs for the treatment of cervical cancer.Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer.Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits.Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.Human papillomavirus and genome instability: from productive infection to cancer

P2860

Q26993238-8D2D08AB-7E18-4F59-BC6F-98CE6D792A4F Q34389368-F951D25A-D015-4857-98CA-182929AC99FC Q34655335-ED2E1DCF-6593-4B2F-9FAF-5B6C5AB77570 Q34700859-2713FE19-314B-4C85-9523-B21F7907DE56 Q36173653-7367AF61-D891-4E90-A006-A4ACFBD25DBA Q36214463-BCC6B0F7-1ADF-48A1-B9A2-8CDC74CE22FE Q36884393-EDA32B57-A928-4DD9-BE93-9C4F1D5E78CB Q36897256-95FEC699-C524-46EA-B686-3373A2C9E703 Q36937771-2DEB91EE-84F8-4610-AC4B-E018CDF601D4 Q37540968-E7A5A832-6274-4BE3-B920-FA373FFAB203 Q38314157-C565D327-A6BF-4BAF-A983-54A6E6ED9AEA Q38341324-CD4D170C-A906-4E30-AD17-DF3DDD80F585 Q38373926-2111C75B-8CAA-4020-A2CB-F865501A1B0F Q38497958-11EC16D0-E3F0-4100-A518-D4A3D8D3ED76 Q38554663-F02AE5C4-6CAF-4050-B57A-B5F8F18E1B64 Q38633525-5FDB2F81-7861-4E85-B49E-FB38A11CC5EF Q38663857-010E49B1-B6B6-4AD6-AFC6-E7D33B204818 Q38706483-4E2FEB3C-9FF2-499E-AEB0-94C98B442DA1 Q38810865-6F007C85-8859-4B3C-BB37-A25580727117 Q38826622-F972C863-100E-4337-9A00-BAEC07FE0991 Q39168925-EC7B91CA-7982-4AFC-9F44-4C6FDA79EB4C Q39287099-BE55F63B-AF5D-4D2E-989B-6D201B226E5B Q41484436-9D326BD9-D450-4C41-8C3F-BEFD1B9DF0EF Q47135351-FC039E8D-626E-45F8-BE66-AF41ADF862D7 Q48149693-FD5AEADC-FFCA-4F43-9FBC-59E2B77A3416 Q58699202-9793B41C-EA29-49D5-8B5C-BA2D6DCDD3E1

P2860

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

http://www.wikidata.org/entity/Q33407093

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Multicenter phase II trial of ...... or persistent cervical cancer.

@ast

Multicenter phase II trial of ...... or persistent cervical cancer.

@en

type

label

Multicenter phase II trial of ...... or persistent cervical cancer.

@ast

Multicenter phase II trial of ...... or persistent cervical cancer.

@en

prefLabel

Multicenter phase II trial of ...... or persistent cervical cancer.

@ast

Multicenter phase II trial of ...... or persistent cervical cancer.

@en

P1433

Q33407093-B06AC926-49B3-4437-BA8C-B127B72E28E2

P1476

Q33407093-27C70704-A271-4EB8-94B4-0FCA78629F9E

P2093

Q33407093-183E8E00-89EC-457A-85D6-BF9C6565F6EB

Q33407093-292941DE-1EFC-43D9-8699-6DB1C252322B

Q33407093-436218CB-2969-45FA-B06A-9F4A234AB3E0

Q33407093-495677C9-77C7-47F2-961D-F61CC2244245

Q33407093-6879D755-8BCB-4572-947C-3CD1170D2F1E

Q33407093-6C0F5BB8-FC25-456D-A64C-146F25086AE1

Q33407093-77E1664F-99CA-4863-A436-11DD6F515F3A

Q33407093-8BEBB4CF-4066-4EBA-BEA6-7FD8FD662E91

Q33407093-B8BBE898-5781-4387-826E-A959E91BA822

Q33407093-C77766DF-4F97-4B15-BB51-F2671F4B9375

P2860

Q33407093-00DC0FB1-973A-4439-A848-90D4F24AE6B3

Q33407093-0F324162-165E-4914-B40D-5D95FE00F60B

Q33407093-1E0A4468-F92E-44A4-BC30-41A933C53FF1

Q33407093-1E9D6FA5-3047-4D69-9E50-EEFD0835EF91

Q33407093-2CFCC72D-6CF0-41A4-B878-12775EB8E882

Q33407093-308512E3-4221-45D0-B9DC-91C9B5A13D6A

Q33407093-42195890-DB35-43F8-8922-1C397AFD2D77

Q33407093-469B7240-8377-4753-A19B-B3D02280FFDB

Q33407093-67C39710-267F-4633-8809-78B944AEB724

Q33407093-6E1AC4D0-EF8F-4E81-9036-4227ED661552

P304

Q33407093-8F01E25A-5F7F-4AAB-B3B5-4321EE2097C6

P31

Q33407093-EA15998F-D465-4AF5-80DF-141F96213462

P356

Q33407093-AB1D660E-79BA-4903-8D90-AEDE75572744

P407

Q33407093-2C172461-CC8C-4F98-9A5C-21C8C4A0A49E

P433

Q33407093-0584363B-A24F-487C-AE6D-C92214766355

P478

Q33407093-E6FF6CBE-1705-420F-9BBA-EBC95D524841

P50

Q33407093-23B19474-6ECA-45CC-AF9D-595F23BB3BB4

Q33407093-57AA8363-BDD1-4E16-A07B-5EEE2780352E

Q33407093-C595EB34-943E-4585-99C5-EED1C30B841C

P577

Q33407093-8A9E8FEA-D9DB-49A4-BE56-D1F34B46BF01

P698

Q33407093-1BA900D7-C2E4-4C42-8207-6B3CA8674937

P921

Q33407093-8843950D-E71B-4093-BC03-7E233073724D

Q33407093-A6E873E4-3112-4417-9357-018082D5C397

Q33407093-E955B788-4A85-4DDE-9B5A-14F4818B99BA

P932

Q33407093-9F95A4EE-9B23-4754-8DC3-FE4194F1966C

P356

J.YGYNO.2013.04.009

P1433

Gynecologic Oncology

P1476

Multicenter phase II trial of ...... or persistent cervical cancer.

@en

P2093

Ashley S Case

http://www.w3.org/2001/XMLSchema#string

David G Mutch

http://www.w3.org/2001/XMLSchema#string

Eric L Eisenhauer

http://www.w3.org/2001/XMLSchema#string

Farrokh Dehdashti

http://www.w3.org/2001/XMLSchema#string

Fidel A Valea

http://www.w3.org/2001/XMLSchema#string

Israel Zighelboim

http://www.w3.org/2001/XMLSchema#string

Janet S Rader

http://www.w3.org/2001/XMLSchema#string

Jason D Wright

http://www.w3.org/2001/XMLSchema#string

L Stewart Massad

http://www.w3.org/2001/XMLSchema#string

Lynne T Lippmann

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Radiation therapy alone in the treatment of carcinoma of the uterine cervix: review of experience at Tokyo Women's Medical College (1969-1983).

Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.

P304

64-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2013.04.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Angeles Alvarez Secord

P577

2013-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23591400

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

3870479

http://www.w3.org/2001/XMLSchema#string